← 返回

免疫代谢重编程:癌症免疫治疗的新前沿

英文原题:Immunometabolic Reprogramming: A New Frontier in Cancer Immunotherapy.

查看英文原题

Immunometabolic Reprogramming: A New Frontier in Cancer Immunotherapy.

PubMed 2026/06/10(内容时间) Curr Mol Med Q3 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

细胞代谢与免疫功能之间的相互作用,即免疫代谢,被认为是决定抗肿瘤免疫及癌症免疫治疗疗效的关键因素。了解不同免疫细胞亚群及癌细胞的代谢依赖性和脆弱性,使研究者能够探索新型治疗策略。这些策略旨在重编程肿瘤微环境(TME)的代谢格局,以增强抗肿瘤免疫应答并克服对现有免疫疗法的耐药。本综述全面概述免疫代谢的基本原理,详细介绍免疫细胞和癌细胞中的关键代谢通路及调节因子。我们探讨不同免疫细胞亚群的特异性代谢谱及其在抗肿瘤应答过程中的变化,并讨论癌细胞的代谢特征及其在不同癌症类型间的差异。随后,综述免疫检查点抑制剂及CAR-T 细胞疗法等现有免疫疗法如何影响细胞代谢,以及代谢如何反过来影响这些疗法。最后,我们重点介绍靶向免疫代谢的有前景治疗机会,包括代谢抑制剂、调节剂及联合策略。本综述旨在将免疫代谢重编程阐述为提高癌症免疫治疗疗效、改善患者结局的新前沿。

展开英文摘要原文

The interaction between cellular metabolism and immune function, termed immunometabolism, has been regarded as a crucial determinant of anti-tumor immunity and the efficacy of cancer immunotherapy. Understanding the metabolic dependencies and vulnerabilities of various immune cell subsets and cancer cells is enabling researchers to study novel therapeutic strategies.

These strategies aim to reprogram the metabolic landscape of the TME to enhance stronger anti-tumor immune responses and overcome resistance to current immunotherapies. This review provides a comprehensive overview of the fundamental principles of immunometabolism, detailing the key metabolic pathways and regulators in immune and cancer cells.

We explore the distinct metabolic profiles of various immune cell subsets and how they are altered during an anti-tumor response.

Furthermore, we discuss the metabolic hallmarks of cancer cells, considering variations across different cancer types. Then, we discuss how current immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, impact and are influenced by cellular metabolism.

Finally, we highlight promising therapeutic opportunities for targeting immunometabolism, including metabolic inhibitors, modulators, and combination strategies. This review aims to introduce immunometabolic reprogramming as a new frontier to enhance the efficacy of cancer immunotherapy and improve patient outcomes.

论文信息

作者
Mohammadi S、Darweesh M、Rahmati M、Al-Hamadani M、Ahmadaghdami M、Al-Harrasi A
第一作者单位
Immunology Laboratory, Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
通讯作者单位
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
期刊
Current molecular medicine2026 Jun 10
原文标识
PubMed 42300295 · DOI 10.2174/0115665240435650260516221100